Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

Full DD Report for BVXV

You must become a subscriber to view this report.


Recent News from (NASDAQ: BVXV)

BiondVax to Present at Influenza 2018 Oxford Conference
JERUSALEM , Sept. 4, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford . Joshua Phillipson , Biond...
Source: PR Newswire
Date: September, 04 2018 06:15
BiondVax Announces Second Quarter 2018 Financial Results
JERUSALEM , Aug. 22, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended ...
Source: PR Newswire
Date: August, 22 2018 07:00
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, Inc. (NASDAQ:MNOV), Dermira, Inc. (NASDAQ:DERM), FRP Holdings...
Source: GlobeNewswire
Date: August, 20 2018 07:50
BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
JERUSALEM , Aug. 20, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of the M-001 universal influenza vaccine candidate, reported today the company's relocation to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel . ...
Source: PR Newswire
Date: August, 20 2018 07:00
BiondVax Receives Second Euro6M Tranche Disbursement From the European Investment Bank (EIB)
NESS ZIONA, Israel , Aug. 14, 2018   /PRNewswire/ --- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Ban...
Source: PR Newswire
Date: August, 14 2018 06:00
First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
NESS ZIONA, Israel , Aug. 8, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported today the first participant's initial visit in a pivotal clinical efficacy Phase 3 trial of the M-001 universal flu vaccine candidate. The primary endpoints of the trial are...
Source: PR Newswire
Date: August, 08 2018 08:30
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
NESS ZIONA, Israel , June 28, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain as Vice-Chairman of its Board of Directors. ...
Source: PR Newswire
Date: June, 28 2018 07:00
BiondVax Receives Its First Euro6M Tranche Disbursement From the European Investment Bank (EIB)
NESS ZIONA, Israel , June 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB...
Source: PR Newswire
Date: June, 19 2018 09:00
Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals - New Research Emphasizes Economic Growth
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV), MercadoLibre, Inc. (NASDAQ:...
Source: GlobeNewswire
Date: June, 05 2018 07:45
BiondVax Announces First Quarter 2018 Financial Results
NESS ZIONA, Israel , May 29, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its financial results for the quarter ended Mar...
Source: PR Newswire
Date: May, 29 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-115.295.255.374.9215,720
2018-12-105.565.405.565.403,471
2018-12-07N/A5.65N/AN/A4
2018-12-065.405.655.675.40532
2018-12-055.905.42715.905.42713,227

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-113,8205,09075.0491Short
2018-12-107031,58944.2417Short
2018-12-0733100.0000Short
2018-12-0450250799.0138Short
2018-12-031831,46312.5085Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BVXV.


About BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

Logo for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BVXV)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 01 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: April, 30 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 18 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 21 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 14 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 22 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 22 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: January, 24 2018

       

       


      Daily Technical Chart for (NASDAQ: BVXV)

      Daily Technical Chart for (NASDAQ: BVXV)


      Stay tuned for daily updates and more on (NASDAQ: BVXV)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BVXV)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BVXV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BVXV and does not buy, sell, or trade any shares of BVXV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/